Detection of tumor-associated antigens in culture supernatants using autoantibodiesin sera from patients with bladder cancer

  • MINAMI Sho
    Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kitasato1-15-1,Minami-ku, Sagamihara-shi, Kanagawa 252-0373, Japan
  • NAGASHIO Ryo
    Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kitasato1-15-1,Minami-ku, Sagamihara-shi, Kanagawa 252-0373, Japan Department of Molecular Diagnosis, School of Allied Health Sciences Kitasato University, Kitasato1-15-1,Minami-ku, Sagamihara-shi, Kanagawa 252-0373, Japan
  • UEDA Junpei
    Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kitasato1-15-1,Minami-ku, Sagamihara-shi, Kanagawa 252-0373, Japan
  • MATSUMOTO Kazumasa
    Department of Urology, School of Medicine, Kitasato University, Kitasato1-15-1,Minami-ku, Sagamihara-shi, Kanagawa 252-0373, Japan
  • GOSHIMA Naoki
    National Institute of Advanced Industrial Science and Technology, 2-42Aomi, Koto-ku, Tokyo 135-0064, Japan
  • HATTORI Manabu
    Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kitasato1-15-1,Minami-ku, Sagamihara-shi, Kanagawa 252-0373, Japan National Institute of Advanced Industrial Science and Technology, 2-42Aomi, Koto-ku, Tokyo 135-0064, Japan
  • HACHIMURA Kazuo
    Department of Molecular Diagnosis, School of Allied Health Sciences Kitasato University, Kitasato1-15-1,Minami-ku, Sagamihara-shi, Kanagawa 252-0373, Japan
  • IWAMURA Masatsugu
    Department of Urology, School of Medicine, Kitasato University, Kitasato1-15-1,Minami-ku, Sagamihara-shi, Kanagawa 252-0373, Japan
  • SATO Yuichi
    Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kitasato1-15-1,Minami-ku, Sagamihara-shi, Kanagawa 252-0373, Japan Department of Molecular Diagnosis, School of Allied Health Sciences Kitasato University, Kitasato1-15-1,Minami-ku, Sagamihara-shi, Kanagawa 252-0373, Japan

この論文をさがす

抄録

Secreted proteins play essential roles in the process of tumorigenesis, and the analysis of tumorsecretedproteins has been suggested as a promising strategy for identifying cancer biomarkers. Inthis study, we performed proteomic analysis to identify proteins secreted from bladder cancer celllines that are recognized by autoantibodies in sera from patients with bladder cancer. In addition,autoantibodies against the identified proteins were validated using a dot-blot array with sera frompatients with bladder cancer and normal controls. As the results, we detected twenty-five and thirty-two immunoreactive spots in sera from patients with high- and low-grade bladder cancer, respectively.In addition, validation analysis revealed that serum IgG levels of anti-calreticulin andmatrix metalloproteinase-2 (MMP2) autoantibodies were significantly higher in bladder cancer patientsthan in normal controls (both P < 0.05). Furthermore, the serum IgG level of anti-MMP2autoantibody was significantly higher in patients with high- compared to low-grade bladder cancer(P < 0.05). On multivariate analysis, the serum IgG level of anti-MMP2 autoantibody was an independentpredictor of cancer-specific survival (P < 0.05). Based on these findings, serum IgG levelsof anti-calreticulin and MMP2 autoantibodies may be novel biomarker candidates for bladdercancer and its clinical outcome.

収録刊行物

  • Biomedical Research

    Biomedical Research 35 (1), 25-35, 2014

    バイオメディカルリサーチプレス

被引用文献 (7)*注記

もっと見る

参考文献 (41)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ